Tumor-specific evaluation should include histopathological confirmation with tumor grading based on the Ki-67 index, along with assessment of somatostatin receptor (SSTR) expression using SSTR PET/CT, such as [68]Ga-DOTATATE or [64]Cu-DOTATATE PET/CT, which is essential for determining eligibility for PRRT [33, 90]. The gene discussed is MKI67; the disease is neoplasm.